Market Research Blog – Page 1016 – New Product Development

Wi-Fi Semiconductor Chipset Market Poised for Growth, Valued at $20.1 Billion in 2022 | FMI

The global Wi-Fi semiconductor chipset market is expected to reach US$ 20.1 Billion in 2022. It is projected to surpass US$ 26.3 Billion and exhibit growth at a CAGR of 5.2% from 2022 to 2032. The increasing penetration of the internet and the rising number of public Wi-Fi hotspots across the globe are likely to fuel the demand for Wi-Fi semiconductor chipsets in the near future.

A recent market research study on the Wi-Fi Semiconductor Chipset market was released by Future Market Insights. The study offers a thorough analysis of the Wi-Fi Semiconductor Chipset market’s historical data, present situation, and potential future growth.

The important trends and growth variables that are expected to have an impact on the market in the upcoming years are meticulously examined in the report. During the projected period, it is anticipated that the adoption of cloud computing and artificial intelligence would advance the technology industry.

Increased competitive pressure and an expedited digital transformation in the areas of data analytics and artificial intelligence are expected to boost the growth prognosis for the Wi-Fi Semiconductor Chipset market in the upcoming decade.

According to the FMI report, substantial product advancements, shifts in consumer behavior, and expanding distribution networks all continue to have an effect on the market for Wi-Fi semiconductor chipsets. The FMI analysts who created the Wi-Fi Semiconductor Chipset market study used novel research methods, in-depth data analysis, and collection from a range of primary and secondary sources.

Impact of COVID-19 on Wi-Fi Semiconductor Chipset Market

The IT industry has been significantly impacted by the start of COVID-19. The technology sector has suffered from disruptions in the raw material supply and electronic supply-value chain. The introduction of remote working has, however, had a favorable effect on the sector. A positive outlook is anticipated as a result of the quick focus on integrating digital techniques and big data analytics in IT services and the technology sector.

The COVID-19 effect analysis is the sole focus of a chapter of a recent report from FMI. This is meant to assist Wi-Fi Semiconductor Chipset market participants in implementing creative solutions to deal with problems that could potentially affect the market.

Key Questions Addressed in the Wi-Fi Semiconductor Chipset Market Report

How will the Wi-Fi Semiconductor Chipset market expand through 2031?
Which are the major key growth drivers and opportunities driving the market growth?
What are the recent technological developments in the Wi-Fi Semiconductor Chipset market?
What are key challenges and competition threats faced by Wi-Fi Semiconductor Chipset market players?
Which region is the most lucrative in the Wi-Fi Semiconductor Chipset market?

Market Competition

Some of the key players operating in the global Wi-Fi semiconductor chipset market are Qualcomm Technologies, Inc., Broadcom Inc., MediaTek Inc., Intel Corporation, Texas Instruments Incorporated., Hewlett Packard Enterprise Co., STMicroelectronics N.V., Samsung Electronics Co., Ltd., NXP Semiconductors N.V., On Semiconductor Co., Inc., Skyworks Solutions, Inc., Cisco Systems Inc., Simcom Wireless Solutions Limited, Peraso Technologies, Inc., Cypress Semiconductor Corporation, Dell Technologies, CommScope Holding Co., Quectel, Extreme Networks, and ASUS.

Leading players are focusing on upgrading organizations’ data transfer and bandwidth rate over wireless communication with the ongoing development in the field of IoT technology. Meanwhile, some of the other prominent companies are engaging in acquisitions and new product developments to cater to the increasing consumer demand globally by expanding their existing product portfolios.

Key Segments Profiled in the Wi-Fi Semiconductor Chipset Industry Survey

MIMO Configuration:

SU-MIMO
MU-MIMO

Band:

Single & dual-band
Tri-band

IEEE Standard:

11be (Wi-Fi 7)
11ax (Wi-Fi 6 and 6E)
11 ac (Wi-Fi 5)
11ad
11b/g/n

Vertical:

Consumer Electronics
Enterprise
Industrial
Retail
BFSI
Healthcare
Automotive
Others (Government & Public Sector)

End Use:

Consumer Devices
Cameras
Gaming Devices
AR/VR Devices
Mobile Robots
Drones
Networking Devices
mPOS
In-vehicle Infotainment
Others

Region:

North America
Latin America
Western Europe
Eastern Europe
APEJ
Japan
Middle East and Africa

Request a Sample of This Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-722

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

On-site Preventive Care Market to Reach USD 43.52 Billion by 2034 at a 5.2% of CAGR

The global on-site preventive care market is expected to experience robust growth, with a projected valuation of USD 26.21 billion in 2024. According to industry forecasts, the market is anticipated to rise at a compound annual growth rate (CAGR) of 5.2% over the next decade, reaching an estimated USD 43.52 billion by 2034.

On-site preventive care services, which focus on providing healthcare at workplaces or other convenient locations, are gaining widespread adoption due to their ability to reduce healthcare costs and improve overall employee wellness. These services encompass a range of offerings, including health screenings, vaccinations, wellness programs, and lifestyle management initiatives aimed at preventing chronic diseases and promoting healthier lifestyles.

With the increasing emphasis on proactive health management and the growing recognition of the benefits of early disease detection, businesses and healthcare providers are expanding their on-site preventive care solutions. The market’s growth is further bolstered by the rising awareness of the importance of preventive healthcare in reducing long-term healthcare costs and improving workforce productivity.

On-site preventive care, which includes services such as health screenings, vaccinations, and wellness programs delivered directly at workplaces and other locations, is gaining traction as organizations increasingly focus on employee health and well-being. The market’s expansion is driven by the rising recognition of the benefits of preventive care in reducing healthcare costs and improving overall productivity.

The growing emphasis on maintaining a healthy workforce, coupled with the increasing adoption of innovative on-site health solutions, is contributing to the robust growth of this market. Organizations are investing in preventive care services to proactively address health issues, minimize absenteeism, and enhance employee engagement and satisfaction.

This anticipated growth highlights the increasing emphasis on preventive care solutions delivered directly at the site of care, driven by the need to enhance health outcomes, reduce costs, and improve patient access to medical services. The rise in adoption of on-site preventive care is attributed to its effectiveness in managing health proactively and its role in reducing the burden on traditional healthcare systems.

Prioritizing Prevention

This surge in demand for on-site preventive care reflects a growing emphasis on maintaining health and well-being before the onset of illness. This proactive approach aligns perfectly with the Human Development Index (HDI) concept, which considers life expectancy a key factor in evaluating a society’s overall development. Businesses are recognizing the benefits of investing in employee health, and on-site preventive care programs offer a convenient and accessible solution for employees.

On-site clinics enable employees to receive the required essential care at the time of emergency without having to leave the workplace. The clinicians in these clinics also aid employees in searching for a primary care physician whom they can consult with regularly. As a Future Market Insights analyst quotes, “Changes in lifestyle among the working class have incessantly impelled employers to establish certain behavioural standards within the workplace. This is one of the core factors responsible for the growing adoption of on-site preventive care in several organizations across the globe.”

North America and Western Europe to Compete Neck and Neck

In 2017, North America held a share of 37.0% in the global on-site preventive care market closely trailed by Western Europe. The dominance of North America can be attributed to the several policies implemented by the U.S. government about employee safety and the adoption of certain employee codes of safety. The U.S. is also an extremely mature market owing to the high adoption of workplace wellness programmes.

Burgeoning Penetration of Workplace Wellness Programmes to Bode Well for the Market

In the recent past, workplace wellness programmes have earned the merit of being one of the most adopted healthcare services in the world. It has been further expected that its adoption will increase in the coming years owing to the implementation of the Affordable Care Act. This act is expected to promote an increase in the employee-based coverage of workplace wellness and also promote these programmes through several provisions. Moreover, the growing incidences of chronic diseases among the working population have also become a matter of concern and this has compelled employers across the globe to adopt as well as promote workplace wellness programmes.

Furthermore, employers who have adopted on-site preventive care services have reported enhanced performance ranging from heightened morale and cost savings to productivity. The death of time, access, and cost along with misunderstanding of the benefits of prescribed wellness programmes result in the underutilisation of primary care services. As a result, employees flood emergency rooms, missing out on critical preventive care measures and also leaving chronic conditions unmanaged. In this regard, on-site clinics provide employees with the necessary support without having to leave their work and the clinicians also work together with the patients in a cohesive environment to address their various health-related issues.

Companies to Innovate Services in the On-site Preventive Care Market

To stay ahead of the competition, several companies operating in the global market are focussing on innovating their existing services and integrating new services. Some of the leading companies in the market are Premise Health, OnSite Care, Inc., PrevMED, RepuCare, Healthcare Solutions Centers, LLC, McCormack & Kale Motiva Health & Chiropractic, Inc., Marino Wellness, Kinema Fitness, and TotalWellness.

A Old Full Report Analysis Click Here

Key Segments Covered in On-site Preventive Care Market Research

By Service Type

Acute Care
Chronic Disease Management
Wellness and Coaching
Nutrition Management
Diagnostic and Screening
Others

By Management Model

In-house Management Model
Hybrid Management Model
Outsourced Management Model

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Anaesthesia Machines Market Expected to Reach USD 17,780.9 Million by 2034 at a 4.8% of CAGR

The global anesthesia machines market is poised for steady growth, with sales projected to be worth USD 11,126.0 million in 2024. By 2034, the market is anticipated to reach a value of USD 17,780.9 million, reflecting a compound annual growth rate (CAGR) of 4.8% over the forecast period from 2024 to 2034. In 2023, the market generated revenue of USD 10,616.4 million.

This growth is being driven by the increasing demand for advanced an aesthesia machines across healthcare facilities worldwide. Technological advancements, coupled with the rising number of surgical procedures, have led to greater adoption of modern anaesthesia systems that offer enhanced safety, precision, and efficiency in patient care.

As healthcare infrastructures expand globally, particularly in emerging economies, the need for reliable and state-of-the-art anaesthesia machines is expected to continue rising. The push for better healthcare delivery and the growing focus on patient safety further support the growth of this market.

Key Trends and Highlights in the Anaesthesia Machines Market

A noticeable shift in the anaesthesia machines landscape is the increasing portability and compactness of these devices, enabling their use in remote and underserved areas, as well as ambulatory surgery centres.

The rising preference for non-invasive and minimally invasive medical procedures, characterized by their low risk and faster recovery times, is a prominent driver of demand. As these procedures gain popularity, there is an expected surge in the demand for anaesthesia machines that support these advanced techniques.

Continuous advancements in the design of anaesthesia machines have been observed to improve operating efficiency, patient safety, outcome, and convenience. Market participants are concentrating on new product development and the launch of innovative products with enhanced features and capabilities.

Anesthesia apparatuses are medical devices used to deliver anaesthesia to patients during surgical or other medical procedures. These machines are designed to deliver a precisely controlled mixture of gases, including oxygen, nitrous oxide, and various anaesthetic agents, to the patient’s lungs.

The research report “Anaesthesia Machines Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” published by Future Market Insights throws light on several aspects driving the global market. The growth of the market is impacted by various trends, developments, drivers and challenges, the analysis of which is included in the fact-based research report. The exhaustive research publication covers historical data analysis along with current scenarios as well as future projections of the market from a value standpoint for 10 years, starting from 2017 till 2027. The analysis of various segments playing a major role in the expansion of the global anaesthesia market has been carried out to get a complete picture of the global market.

Increasing Need for Anaesthesia Procedures to Spur the Adoption of Anaesthesia Machines in the Coming Years

According to WHO (World Health Organization) and World Bank, by 2026, the treatments demanding surgeries and hence anaesthesia machines would eclipse that of tuberculosis and HIV as well as malaria. The current market scenario portrays the fact that about 30% of the population in the entire globe does not have access to surgeries. On the contrary, about 75% of major procedures are being performed in the wealthiest countries in the world whereas poor countries are witnessing only 3.5% of operations.

Government bodies along with non-government institutions are continuously working on offering healthcare access to every region, which is expected to trigger the adoption of anaesthesia machines. The growing number of surgeries and increasing government support are expected to fuel the growth of the anaesthesia machines market at a global level in the years to follow.

However, product recalls due to defects in devices, shortage of healthcare professionals, adoption of refurbished machines, lack of public access to healthcare facilities and lack of clinical resources are expected to pose hindrances to the growth of the global market.

Segmental Highlights on the Anaesthesia Machines Market

Concerning region, North America and Asia Pacific excluding Japan (APEJ) are expected to showcase high growth potential. The Anaesthesia machines market in North America (led by the US) is estimated to be the largest, whereas the market in APEJ is expected to rise at a comparatively high-value CAGR during the forecast period
Concerning modality, standalone anaesthesia machines are expected to witness increased adoption across the globe in several hospitals and clinics. This segment is expected to lead the global market with a high valuation and is projected to expand at a relatively high CAGR throughout assessment

Anaesthesia Machines Market Key Segments Covered:

By Modality

Standalone Anaesthesia Machines
Portable Anaesthesia Machines

By End User

Hospitals
Surgical Ambulatory Centres
Clinics
Nursing Facilities

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Orthokeratology Market Set to Reach USD 659.1 Million by 2034 at a 4.80% of CAGR

The global orthokeratology market is poised for steady growth over the coming decade, with an estimated market value of USD 412.4 million in 2024. By 2034, the market is projected to reach USD 659.1 million, registering a compound annual growth rate (CAGR) of 4.80% over the forecast period.

Orthokeratology, a non-surgical treatment used to temporarily reshape the cornea to improve vision, has gained increasing popularity as a safe and effective alternative to corrective lenses and surgery. The rising prevalence of myopia, especially in children and young adults, is one of the key drivers of market growth, as orthokeratology offers an effective solution for managing this condition.

In addition to its benefits for myopia control, orthokeratology is gaining traction due to growing awareness of eye health, advancements in lens technology, and an increasing number of eye care professionals offering this treatment.

Orthokeratology, a non-surgical procedure that uses specially designed contact lenses to temporarily reshape the cornea and correct refractive errors, is gaining popularity as a safe and effective alternative to laser eye surgery. The increasing prevalence of myopia, particularly among children, and the rising demand for non-invasive vision correction solutions are key factors driving market growth.

Orthokeratology, also known as corneal refractive therapy, involves the use of specially designed contact lenses to reshape the cornea and correct vision. The growing awareness of the benefits of this non-surgical approach to vision correction is driving demand and contributing to market expansion.

Additionally, high prevalence of chronic diseases like diabetic retinopathy is expected to positively influence the market prospects. Developments such as the emergence of ingenious orthokeratology products and of implantable intraocular lenses will bolster the future possibilities for the orthokeratology market.

Though the orthokeratology market looks forward to an overall healthy future market prospects, it is not without its share of restraints. High initial cost of orthokeratology lenses, increasing cases of corneal infection in pediatric patients, less market penetration of the product along with a lack of skilled professional are factors that may subdue the growth of the orthokeratology market over the forecast period.

“High incidences of myopia and better benefits of Ortho-K lens as compared to the conventional ones are likely to boost the sales of orthokeratology in the global market over the forecast period,” says an FMI analyst.

Key Takeaways:

High initial costs of the lenses may hinder market growth.
The US to account for a major share of market revenue by 2028.
The orthokeratology market in China will record a high CAGR over the forecast period.
By indication, the myopia segment will continue to be a major market driver.
On the basis of distribution channels, optometry clinics will register the highest demand.

Competitive Landscape

The Cooper Companies Inc., Euclid Systems Corporation, Menicon Co., Ltd., GP Specialists, Inc., TruForm Optics, Inc., Art Optical Contact Lens, Inc., MiracLens L.L.C., and Contex, Inc, among others, are some of the major players in the orthokeratology market that are profiled in the full version of the report.

Major market players are focused on establishing stronghold in China and Japan. Mergers and collaborations are certain tactics that these businesses employ to retain a competitive advantage.

More Insights into the Orthokeratology Market Report

In its latest report, FMI offers an unbiased analysis of the global orthokeratology market, providing historical data from 2013 to 2021 and forecast statistics for 2022 to 2028. To understand the global market potential, growth, and range, the market is segmented based on indication (myopia, presbyopia, hyperopia, astigmatism), distribution channel (hospitals, optometry clinics, ophthalmology clinics), and region.

According to the latest FMI reports, based on region, the orthokeratology market in the United States is expected to undergo significant growth over the forecast period. The region is predicted to acquire a major chunk of the global market share by 2028. This growth can be attributed to the presence of a well-developed and established healthcare sector. Favorable government initiatives in the healthcare sector also support this market growth.

In China, the orthokeratology market is projected to exhibit a high CAGR over the forecast period. The region is expected to offer multiple lucrative opportunities to the orthokeratology market. Prolonged usage of electronic devices such as laptop, smartphones, tablets, etc., has led to high rates of chronic eye damage. With high prevalence of myopia and hyperopia, the target market in China is expected to grow at a rapid rate.

Based on segmentation, by indication, the myopia segment will likely create substantial market opportunities while, in terms of distribution channels, optometry clinics will dominate the market over the forecast period.

A Old Full Report Analysis Click Here

Key Segments Covered in Orthokeratology Industry Survey

Orthokeratology Market by Indication:

Myopia
Presbyopia
Hyperopia
Astigmatism

Orthokeratology Market by Distribution Channel:

Hospitals
Optometry Clinics
Ophthalmology Clinics

About Future Market Insights (FMI)

Contact Us:

Meningococcal Vaccine Market to Reach USD 9014 Million by 2034 at a 8.6% of CAGR

The global meningococcal vaccine market is poised for robust growth, with an estimated valuation of USD 3950.2 million in 2024, projected to reach approximately USD 9014 million by 2034. This reflects a significant compound annual growth rate (CAGR) of 8.6% over the forecast period from 2024 to 2034.

The growth of the meningococcal vaccine market is primarily driven by the rising incidence of meningitis cases worldwide. According to recent data, there were approximately 2.51 million global cases of meningitis in 2019, with 1.28 million of these cases occurring in children under the age of five. The severity and potential fatality of the disease have heightened concerns, prompting a growing number of people to seek vaccination.

This trend is especially notable in countries with well-established healthcare infrastructures, such as the United States, the United Kingdom, India, and China, where proactive vaccination programs are gaining momentum. As awareness of the importance of meningitis prevention continues to rise, the demand for meningococcal vaccines is expected to increase significantly over the coming decade.

In a recent report, FMI unveils groundbreaking insights, positioning the conjugate vaccines segment as the industry frontrunner, commanding an impressive 62.6% revenue share in 2021. This highlights the pivotal role of conjugate vaccines in shaping the market landscape and steering its overall success.

The anticipated growth in the Global Meningococcal Vaccines Industry reflects a collective effort towards enhancing global healthcare and preventing the spread of meningococcal diseases. With advancements in vaccine technologies and increasing awareness about the importance of immunization, the industry is set to play a pivotal role in safeguarding public health.

Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives.

The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need.

The governments of several countries across the globe initiate immunisation programmes periodically and these programmes are backed by global organisations such as UNICEF and WHO and private not-for-profits like the Global Alliance for Vaccines and Immunization (GAVI).

A classic example of how private-public partnerships are helping boost vaccination programmes across deep regional pockets is Brazil.

In 2010, Ezequiel Dias Foundation, Brazil formed a strategic alliance with Novartis Vaccines & Diagnostics for the sustainable supply of Menjugate MenC vaccines for Brazil’s National Immunization Program. By 2015, Brazil became self-sufficient in the production of the meningococcal C conjugated vaccine for the country’s public vaccination programmes. Such initiatives at the global level are anticipated to support global immunisation goals and at the same time boost the growth of the Global Meningococcal Vaccines Industry

Key Companies Profiled in the Global Meningococcal Vaccines Industry:

Sanofi Pasteur Inc.
GlaxoSmithKline Plc
Wyeth Pharmaceuticals
Bio-Manguinhos
Bio-Med Pvt. Limited
Chongqing Zhifei Biological Products Co., Ltd.
Hualan Biological Engineering Inc.
Incepta Pharmaceuticals Ltd.
Pfizer INC
Serum Institute of India Pvt. Ltd
Walvax Biotechnology Co., Ltd.

Factors Leading to Worldwide Adoption of Meningococcal Vaccination Programmes

The Global Meningococcal Vaccines Industry is expected to be driven by enhanced access to vaccines in low and middle-income countries, growing investments by manufacturers and governments to cope with pandemic meningitis outbreaks, and rapidly growing consumption of meningococcal vaccines bolstered by immunisation alliances and mass vaccination campaigns among others.

Partnerships and alliances between manufacturers and governmental healthcare organisations are facilitating the speedy introduction of vaccines in some of the economically challenged countries of the Middle East and Africa region. Enhanced access to vaccines in under-penetrated global markets is expected to accelerate revenue growth of the global meningococcal vaccines market.

Approval of new vaccines in the U.S and Europe in 2015 and 2017 to treat meningococcal meningitis has revolutionised the global immunisation landscape. This is further boosting the growth trajectory of the global market for meningococcal vaccines.

GlaxoSmithKline to Lead the Global Meningococcal Vaccines Industry with About 50% Market Share Recorded in 2017

The Global Meningococcal Vaccines Industry is highly consolidated, with GlaxoSmithKline and Sanofi together holding about 80% of the global market share in 2017. Pfizer is the third largest company in this market with just under 12% market share in 2017.

Companies are expanding their production capacities through the acquisition of established vaccines production units of other global or local companies.

Sanofi has a huge pipeline of 17 active meningococcal vaccines programmes and is targeting emerging markets; while GlaxoSmithKline has 5 active pipeline programmes for meningococcal vaccines, all of which are in the phase II clinical stage. Addition of the vaccine Bexsero has enabled GlaxoSmithKline to defend its brand against Sanofi’s aggressive portfolio in the paediatric vaccines space.

Why Future Market Insights?

Comprehensive analysis on evolving purchase pattern across different geographies
Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Groundbreaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Key Market Segments Covered in Meningococcal Vaccines Industry Research

By Product:

Polysaccharide
Conjugate

By Age Group:

Infants
Children
Adolescents and Young Adults
Adults

By Distribution Channel:

Pharmacies
Community Clinics
Public Health Agencies
Others (hospital pharmacy, private market etc.)

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Veterinary Molecular Diagnostics Market to Surpass USD 377.22 Million by 2033 at a 6.84% of CAGR

The global veterinary molecular diagnostics market is projected to experience significant growth over the next decade. Valued at USD 194.47 million in 2023, the market is expected to exceed USD 377.22 million by 2033, registering a compound annual growth rate (CAGR) of 6.84% during the forecast period.

This growth is driven by increasing demand for accurate and early disease detection in animals, as well as rising awareness about animal health and preventive veterinary care. Veterinary molecular diagnostics provide advanced solutions for diagnosing infectious diseases, genetic disorders, and other health conditions in animals, ensuring better treatment outcomes.

As the global pet population continues to grow, coupled with advancements in veterinary healthcare technologies, the need for reliable molecular diagnostics is on the rise. Additionally, the growing importance of livestock health, fueled by the expanding animal husbandry industry, is further contributing to the demand for these diagnostics.

This significant growth is driven by increasing demand for advanced diagnostic tools that enhance the accuracy and efficiency of veterinary care. The rising adoption of molecular diagnostics in veterinary practices is improving disease detection, management, and prevention, which is contributing to the market’s expansion.

The market is segmented based on product type, disease type, species type, end-user, and region. On the basis of product type, the market has been segmented into four segments such as PCR kits, INAAT kits, microarray kits, DNA sequencing kits.

PCR kits segment is expected to be the fastest-growing segment over the forecast period, registering a significant CAGR of 7.8% in terms of revenue, over the forecast period. The increasing demand for advanced veterinary molecular diagnostic kits, such as RT-PCR kits, DNA sequencing kits, and microarray-based diagnostic kits owing to the growing number of diagnostic procedures in livestock and companion animals worldwide is expected to boost the growth of the veterinary molecular diagnostics market over the forecast period.

The PCR kits segment dominates the market with a market value of US$ 63.4 Mn in 2017. Also, the segment is expected to maintain its dominance over the forecast period with a market value of US$ 124.0 by 2026 end and expands at a significant CAGR.

On the basis of disease type, the market has been segmented into Anaplasma spp., Ehrlichia spp., New Castle Disease, Influenza, Porcine Reproductive & Respiratory Syndrome (PRRS), and others.

Based on species type, the market has been segmented into livestock animals including Aquatic, Bovine, Porcine, Ovine, Poultry, and Equine.

On the basis of end-user, the market has been segmented into veterinary hospitals, clinical laboratories, and veterinary research institutes.

On the basis of region, the market has been segmented into North America, Latin America, Europe, the Asia Pacific Excluding China (APEC), China, and the Middle East and Africa (MEA).

Increasing set up of new production facilities by the key manufacturers in growing economies coupled with increasing adoption of molecular diagnostic techniques in animals is anticipated to boost the production for molecular diagnostic kits and drives the growth of the veterinary molecular diagnostics market over a forecast period.

The increasing prevalence of chronic disorders in animals such as influenza, new castle disease, and diabetes coupled with the high prevalence of infectious diseases is further anticipated to fuel the demand for the veterinary molecular diagnostics market. Increasing preference for molecular diagnosis on the account of their high specificity and efficacy in diagnosing chronic diseases in animals and the presence of a strong distribution channel is further anticipated to drive the growth of the veterinary molecular diagnostics market over the forecast period. Rising adoption of pets, increasing financial grants for innovation in veterinary diagnostics, fast FDA approvals for reagents used in animal molecular diagnostics, and increased consumer spending on veterinary care is also expected to drive the market revenue growth over the forecast period.

Increasing spending on pet care in developing economies such as Japan and India in the APEC region is anticipated to have a positive impact on the veterinary molecular diagnostics market in the APEC region. However, the increasing demand for advanced veterinary molecular diagnostic kits, such as RT-PCR kits, DNA sequencing kits, and microarray-based diagnostic kits owing to the growing number of diagnostic procedures in livestock and companion animals is further anticipated to drive the growth of the veterinary molecular diagnostics market in North America and Europe over the forecast period.

However, gaps in epidemiological knowledge of certain virulent veterinary diseases, high costs associated with veterinary molecular diagnosis and stringent regulatory approval process for novel molecular diagnostic kits resulting into product delays, may hamper the demand for veterinary molecular diagnostic kits and restrain the growth of veterinary molecular diagnostics market over forecast period. Also, the improper veterinary care research infrastructure in the emerging economies, limited reimbursement policies and Visa restrictions strangling vet practices coupled with shortage of veterinary doctors and colleges are some other factors anticipated to hinder the growth of the global veterinary molecular diagnostics market.

This report assesses trends driving the growth of segmental markets and offers analysis and insights into the regional veterinary molecular diagnostics market. North America is estimated to dominate the veterinary molecular diagnostics market with a maximum value share by the end of 2017. By 2026, North America and Europe markets cumulatively are expected to account for over 67.8% revenue share of the global veterinary molecular diagnostics market by the end of 2026.

Some key companies covered in this report include bioMérieux SA, IDEXX Laboratories, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Neogen Corporation, ID.Vet, INDICAL BIOSCIENCE GmbH, and Veterinary Molecular Diagnostics, Inc. These leading players focus to consolidate their position in the global veterinary molecular diagnostics market by actively participating in activities such as partnerships, mergers, acquisitions and collaborations. Companies focus on extending their product line and expansion of production capacities to meet the growing demands for veterinary molecular diagnostics kits worldwide.

A Old Full Report Analysis Click Here

The global veterinary molecular diagnostics market is segmented as follows:

By Product Type

PCR kits
INAAT kits
Microarray kits
DNA sequencing kits

By Disease Type

Anaplasma spp.
Ehrlichia spp.
New Castle Disease
Influenza
Porcine Reproductive & Respiratory Syndrome (PRRS)
Others

By Species

Livestock Animals
- Aquatic
- Bovine
- Porcine
- Ovine
- Poultry
- Equine
Companion Animals
- Canine
- Feline
- Avian

By End User

Veterinary Hospitals
Clinical Laboratories
Veterinary Research Institutes

About Future Market Insights (FMI)

Contact Us:

Global Gait Trainer Market Expected to Reach USD 456.3 Million by 2028 at a 4.9% of CAGR

The global gait trainer market is projected to grow at a steady compound annual growth rate (CAGR) of 4.9% over the forecast period, according to the latest industry analysis by Future Market Insights. The market, valued at USD 342.7 million in 2022, is expected to reach an estimated USD 456.3 million by the end of 2028.

In 2021, the broader exoskeleton market, valued at USD 4.1 billion, saw gait trainer sales contributing 8% of this total. The growth of gait trainer sales, particularly those designed for individuals with cerebral palsy, is driven by a significant rise in the incidence of this condition. This trend highlights the increasing need for effective rehabilitation solutions tailored to cerebral palsy patients.

Research Methodology

FMI adopts a triangulation methodology to provide accurate and precise market estimations and insights for various medical devices and technologies. This approach primarily relies on patient-level data, the number of procedures, and the capital equipment installation base obtained through experimental techniques. The bottom-up approach is always used to obtain country-specific data and then analyze it to generate global data. This ensures the data’s high quality and accuracy.

In the initial stage, secondary research is conducted to determine the feasibility of the target products/technology categories, segments, product offerings, usage patterns, device lifespan, reimbursement scenarios, adoption rates, and future impact of new technologies. Each piece of information is meticulously analyzed to create a solid foundation for primary research.

Primary research involves the participation of demand-side users, including key opinion leaders, physicians, and surgeons, and supply-side providers of medical devices. These stakeholders provide valuable insights on trends, key treatment patterns, adoption rates, purchasing patterns, technological advancements, patient education, manufacturer effectiveness, pricing, and competitive dynamics. This information is further analyzed throughout the research project to ensure comprehensive and accurate market insights.

To project Year-on-Year (Y-o-Y) growth rates for the market, we conduct a quantitative and qualitative assessment of the fundamental factors driving demand, economic factors and cycles, and growth rates, as well as the strategies used by key players. These Y-o-Y growth projections are adjusted and aligned according to the industry/product lifecycle and utilized to develop holistic market numbers.

Additionally, we analyze the annual reports, investor presentations, SEC filings, 10k reports, and press releases of various companies operating in this market segment to obtain detailed information on market size, trends, opportunities, drivers, restraints, key players, and their market shares. These key companies are classified into tiers based on their revenue, product portfolio, and market presence.

It’s important to note that these are only the initial steps in developing the market size. In addition to disease-related factors, we use our internal proprietary model for forecasting, which takes into account various macroeconomic factors such as per capita healthcare expenditure, disposable income, industry-based demand driving factors, and their impact on the market forecast trends.

A Old Full Report Analysis Click Here

Gait Trainer Market Taxonomy

The Gait Trainer Market has been segmented on the following basis:

End User

Hospitals
Rehabilitation Center
Homecare Setting

Product Type

Gait Trainer Walker
Adult
Pediatric
Treadmill System
Exoskeleton

About Future Market Insights (FMI)

Contact Us:

Orthopedic Trauma Devices Market to Reach USD 21.24 Billion by 2034 at a 6.4% of CAGR

The global orthopedic trauma devices market is expected to witness significant growth over the next decade, with an estimated market size of USD 11.39 billion in 2024. The market is projected to exceed a valuation of USD 21.24 billion by 2034, registering a moderate compound annual growth rate (CAGR) of 6.4%.

This growth is driven by the rising incidence of trauma-related injuries, road accidents, and sports-related fractures, which are fueling demand for advanced orthopedic trauma devices. Innovations in medical technology and the development of minimally invasive procedures are also contributing to market expansion, providing improved outcomes for patients.

As the global aging population increases, the prevalence of osteoporosis and other bone-related conditions is expected to rise, further propelling the need for orthopedic trauma devices. The market’s growth is set to benefit from increased healthcare spending and advancements in orthopedic treatments that focus on faster recovery times and reduced complications.

In conclusion, the global orthopedic trauma devices market is on track for substantial growth, driven by an aging population, technological advancements, and rising demand for effective trauma care solutions. Industry stakeholders are encouraged to continue innovating and developing products that meet the evolving needs of healthcare providers and patients.

Key Companies Profiled:

Medtronic, Inc.
Invibio Ltd.
OsteoMed
Weigao Group Co Ltd.
Arthrex, Inc.
Johnson & Johnson Company
CONMED, Tornier, Inc.
Stryker Corporation
Zimmer Holding Inc.
NuVasive
Medartis
Olympus Corporation

Based on the regional analysis, the global orthopedic trauma devices market will continue to witness dominance of North America, which currently accounts for a major portion of the total revenues. With around 48% value share observed in 2021, North America’s orthopedic trauma devices market is estimated to attain a value in excess of US$ 6 Bn by the end of 2028. Western Europe is also identified to be a key market, holding the second largest position in terms of value.

Manufacturers will however discover attractive opportunities in developing economies, including Asia Pacific, Latin America, and Middle East and Africa. Among the emerging regional markets, Asia Pacific excluding China and Japan (APECJ) is likely to emerge at a relatively higher pace, followed by MEA. China is expected to be the most lucrative market owing to the highest estimated CAGR value over 2022-2028. Strong presence of key companies will reportedly uplift the markets in North America and China.

Key Segments Covered in Orthopedic Trauma Devices Industry Research

Orthopedic Trauma Devices Market by Product Type:

Internal Fixators
- Screws
- Intramedullary Nails
- Plates
- Others (Wires, Pins, Staples)
External Fixators
- Unilateral Fixators
- Circular Fixators
- Hybrid Fixators

Orthopedic Trauma Devices Market by Product Type by End User:

Hospitals
Orthopedic and Trauma Centers
Ambulatory Surgical Centers

Orthopedic Trauma Devices Market by Region:

North America Orthopedic Trauma Devices Market
Latin America Orthopedic Trauma Devices Market
Europe Orthopedic Trauma Devices Market
East Asia Orthopedic Trauma Devices Market
South Asia & Pacific Orthopedic Trauma Devices Market
Middle East & Africa (MEA) Orthopedic Trauma Devices Market

About Future Market Insights (FMI)

Contact Us:

Global Cellulite Treatment Market Expected to Surpass USD 7.37 Billion by 2034 at a 7.2% of CAGR

The global cellulite treatment market is poised for substantial growth, with an estimated valuation of USD 3.67 billion in 2024. Projections indicate that the market will grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2034, reaching an impressive value of over USD 7.37 billion by the end of the forecast period.

The rising prevalence of cellulite, driven by the global obesity epidemic, is a key factor behind this market expansion. Poor dietary habits and increasingly sedentary lifestyles are contributing to higher rates of obesity, which is anticipated to fuel the demand for effective cellulite treatment solutions.

The market growth is further supported by advancements in non-invasive and minimally invasive treatment options, along with increasing consumer awareness of aesthetic wellness. As more individuals seek treatments for cellulite reduction and skin smoothing, industry stakeholders are focusing on innovative technologies to meet this growing demand.

In summary, the global cellulite treatment market is set for remarkable growth over the next decade, driven by rising obesity rates and the demand for advanced aesthetic treatments. Companies in the sector are encouraged to invest in research and development to offer cutting-edge solutions that align with evolving consumer preferences.

This growth is largely attributed to the global obesity epidemic, which is primarily driven by poor eating habits and sedentary lifestyles. The rising prevalence of obesity is anticipated to be a major factor fueling the demand for effective cellulite treatment solutions in the coming decade.

Hard Cellulite is Predicted to Hold an Attractive Market Share shortly

One major driver behind the growth of the cellulite treatment Industry is the increasing number of obese population. There is also an increased number of cases of fat deposition. The people who are comparatively overweight mostly face this problem, in turn triggering the demand for cellulite treatment. These cases have helped people grow aware of cosmetic surgeries and have also broadened the scope of these surgeries in the market. There’s a significant rise in aesthetic procedures taking place worldwide.

Especially in Brazil, where around 5,500 cosmetic surgeons were performing the second highest number of aesthetic procedures after the U.S. Around 1,450,020 minimally invasive and non-surgical procedures were performed in Brazil in 2016. Among different types of cellulite, hard cellulite is expected to register a growth rate of around 7.8% during 2022-2028, which is higher than other cellulite types.

North America Slated for Strongest Projections in the Global Cellulite Treatment Industry

Among the major regional divisions made for the research conducted on the global cellulite treatment Industry, North America shows the strongest prospects with an expected market value of over US$ 2,100 Mn by the end of 2028, growing at an impressive CAGR of 8.1% during the forecast period. The growth is helped by North America’s moderate economy and healthcare market.

Also, in the U.S., a large base of the population, especially youngsters, suffer from fat deposition-related disorders. The region is also ahead of other regions due to its developed economy and advanced facilities. The cellulite treatment involves advanced techniques which are also costly for people to afford. This makes the market more prominent in developed regions like North America.

A Old Full Report Analysis Click Here

Key Segments of Cellulite Treatment Market Survey

by Treatment Procedure:

Non-Invasive Cellulite Treatment
Minimally Invasive Cellulite Treatment
Topical Cellulite Treatment

by Cellulite:

Soft Cellulite
Hard Cellulite
Edematous Cellulite

by End User:

Cellulite Treatment in Hospitals
Cellulite Treatment in Ambulatory Surgical Centres
Cellulite Treatment in Specialized Dermatology Clinics

by Region:

North America Cellulite Treatment Market
Latin America Cellulite Treatment Industry
Europe Cellulite Treatment Market
East Asia Cellulite Treatment Industry
South Asia & Pacific Cellulite Treatment Market
Middle East & Africa (MEA) Cellulite Treatment Industry

Author

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Varicella Zoster Infection Treatment Market Projected to Reach USD 2.0 Billion by 2028 at a 4.1% of CAGR

The global varicella zoster infection treatment market is anticipated to experience significant growth, with estimates indicating a market value of over USD 1.5 billion in 2020. Projections suggest the market will reach approximately USD 2.0 billion by 2028, reflecting a compound annual growth rate (CAGR) of 4.1%.

According to Future Market Insights, acyclovir is expected to maintain a substantial share of over 55.7% in the overall varicella zoster infection treatment market in 2022. This antiviral medication is widely recognized for its efficacy in treating infections caused by the varicella zoster virus, including chickenpox and shingles.

The rising prevalence of varicella zoster infections, coupled with an increasing awareness of the importance of timely and effective treatment, is driving demand for medications in this market. Additionally, ongoing research and development efforts to enhance treatment options and improve patient outcomes are expected to contribute to market growth.

Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, hemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorized by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population.

Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.

To cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships to make use of the technology of the other leading companies and are also focussing on research and development.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and fetal risks of varicella-zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.

These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Varicella Zoster Infection Treatment Market Key Players:

Novartis AG,
Pfizer Inc.,
Abbott Laboratories,
Sun Pharmaceuticals Industries Ltd.,
Valeant Pharmaceuticals International Inc.,
Teva Pharmaceutical Industries Ltd.,
Dr. Reddy’s Laboratories, ltd.,
Mylan N.V. and
GlaxoSmithKline

Varicella Zoster Infection Treatment Market Segmentation – by Category

By Drug Type:

Acyclovir
Valacyclovir
Famciclovir

By Route of Administration:

Oral
Injectable
Topical

By Distribution Channel:

Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us: